(S1 (S (NP (NP (NP (NN Hemostasis)) (CC and) (NP (NN mechanism))) (PP (IN of) (NP (NP (NN action)) (PP (IN of) (NP (JJ selective) (JJ antimetastatic) (NNS drugs))) (PP (IN in) (NP (NP (NNS mice)) (VP (VBG bearing) (NP (NN Lewis) (NN lung) (NN carcinoma))))))) (. .))))
(S1 (S (S (NP (NP (DT The) (JJ selective) (JJ antimetastatic) (NNS agents)) (NP (NP (NP (JJ p--LRB-3,3-dimethyl-1-triazeno-RRB-benzoic) (NN acid) (NN potassium) (NN salt)) (PRN (-LRB- -LRB-) (NP (NN DM-COOK)) (-RRB- -RRB-))) (, ,) (NP (NP (NN 5--LRB-3,3-dimethyl-1-triazeno-RRB-imidazole-4-carboxamide)) (PRN (-LRB- -LRB-) (NP (NN DTIC)) (-RRB- -RRB-))) (CC and) (NP (NN -LRB-+/--RRB-1,2-di-LRB-3,5-dioxopiperazin-1-yl-RRB-propane) (-LRB- -LRB-) (CD ICRF-159) (-RRB- -RRB-)))) (VP (VBP have) (VP (VBN been) (VP (VBN shown) (S (VP (TO to) (ADVP (RB markedly)) (VP (VB depress) (NP (NP (DT the) (NN formation)) (PP (IN of) (NP (JJ spontaneous) (JJ hematogenous) (NNS metastases))) (PP (IN in) (NP (NP (NNS mice)) (VP (VBG bearing) (NP (NN s.c))))))))))))) (. .)))
(S1 (S (S (NP (NP (NN Lewis) (NN lung) (NN carcinoma)) (, ,) (PP (IN with) (NP (NP (DT a) (NN mechanism)) (ADJP (JJ unrelated) (PP (TO to) (NP (NP (NN cytotoxicity)) (PP (IN for) (NP (NN tumor) (NNS cells)))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NNS effects)) (PP (IN on) (NP (NN hemostasis))) (PP (IN of) (NP (NP (NN DM-COOK)) (, ,) (NP (NN DTIC)) (CC and) (NP (NN ICRF-159))))) (VP (VBP have) (ADVP (RB thus)) (VP (VBN been) (VP (VBN examined) (PP (IN in) (NP (NP (NN comparison)) (PP (IN with) (NP (NP (DT those)) (PP (IN of) (NP (NP (DT a) (RB purely) (JJ cytotoxic) (NN agent) (, ,) (NN cyclophosphamide) (, ,)) (PP (IN in) (NP (NP (NNS mice)) (VP (VBG bearing) (NP (NN i.m))))))))))))))) (. .)))
(S1 (S (NP (NP (NN Lewis) (NN lung) (NN carcinoma)) (. .))))
(S1 (S (S (NP (NP (DT The) (NNS parameters)) (VP (VBN considered))) (VP (VBP are) (NP (NP (NP (DT the) (NN number)) (PP (IN of) (NP (NP (NNS platelets)) (CC and) (NP (NP (PRP$ their) (NN aggregability)) (, ,) (NP (NN prothrombin)) (CC and) (NP (JJ partial) (NN thromboplastin) (NNS times)))))) (, ,) (NP (NN plasma) (NN fibrinogen) (NN concentration)) (CC and) (NP (NN tumor) (NN cell) (NN procoagulant) (NN activity))))) (. .)))
(S1 (S (S (NP (JJ Slight) (NNS variations)) (VP (VBP are) (VP (VBN caused) (PP (IN by) (NP (NP (NN drug) (NN treatment)) (PP (IN in) (NP (JJ tumor-bearing) (NNS mice))))) (SBAR (IN as) (S (VP (VBN compared) (PP (IN with) (NP (JJ untreated) (JJ tumor-bearing) (NNS controls))))))))) (: ;) (S (NP (NP (DT the) (NN pattern)) (PP (IN of) (NP (NP (NNS effects)) (PP (IN of) (NP (DT the) (JJ selective) (JJ antimetastatic) (NNS agents)))))) (VP (VBZ does) (RB not) (VP (VB differ) (PP (IN from) (NP (NP (DT that)) (PP (IN of) (NP (NP (NP (DT the) (NN reference) (JJ cytotoxic) (NN compound)) (VP (VBN used))) (, ,) (NP (NN cyclophosphamide))))))))) (. .)))
(S1 (S (S (NP (DT These) (NNS data)) (ADVP (RB thus)) (VP (VBP indicate) (SBAR (IN that) (S (NP (NP (DT the) (NNS effects)) (PP (IN on) (NP (NN hemostasis))) (PP (IN of) (NP (NP (DT the) (NNS drugs)) (VP (VBN examined))))) (VP (MD can) (VP (VB contribute) (ADVP (RB only) (RB marginally)) (PP (TO to) (NP (PRP$ their) (JJ antimetastatic) (NN action))) (, ,) (SBAR (IN since) (S (NP (NP (ADJP (RBR more) (JJ pronounced)) (NNS effects)) (PP (IN on) (NP (NN hemostasis)))) (VP (VBP have) (VP (VBN been) (VP (VBN shown) (S (VP (TO to) (VP (VB be) (VP (VBN required) (S (VP (TO to) (ADVP (RB significantly)) (VP (VB affect) (NP (NN metastasis) (NN formation)))))))))))))))))))) (. .)))
